Multicenter Analysis of Transplant Outcomes for the Newly Defined MDS/AML Entity in the 2022 ICC: Risk Stratification

Yuhua Ru1, Mimi Xu1, Mengqi Xiang1

  • 1National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Jiangsu Key Laboratory of Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, China; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.

Abstract

No abstract available in PubMed .